176 related articles for article (PubMed ID: 20098336)
1. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens.
Kolinsky DC; Hayashi SS; Karzon R; Mao J; Hayashi RJ
J Pediatr Hematol Oncol; 2010 Mar; 32(2):119-23. PubMed ID: 20098336
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric sensorineural hearing loss is a risk factor for late-onset hearing loss in pediatric cancer survivors following cisplatin treatment.
Robertson MS; Hayashi SS; Camet ML; Trinkaus K; Henry J; Hayashi RJ
Pediatr Blood Cancer; 2019 Jan; 66(1):e27494. PubMed ID: 30334605
[TBL] [Abstract][Full Text] [Related]
3. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.
Dean JB; Hayashi SS; Albert CM; King AA; Karzon R; Hayashi RJ
J Pediatr Hematol Oncol; 2008 Feb; 30(2):130-4. PubMed ID: 18376265
[TBL] [Abstract][Full Text] [Related]
4. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.
Orgel E; Jain S; Ji L; Pollick L; Si S; Finlay J; Freyer DR
Pediatr Blood Cancer; 2012 Jun; 58(6):953-8. PubMed ID: 21796767
[TBL] [Abstract][Full Text] [Related]
5. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
6. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
7. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
9. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.
Weissenstein A; Deuster D; Knief A; Zehnhoff-Dinnesen AA; Schmidt CM
Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):131-6. PubMed ID: 22104469
[TBL] [Abstract][Full Text] [Related]
10. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
11. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
13. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
14. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
Schmidt CM; Bartholomäus E; Deuster D; Heinecke A; Dinnesen AG
HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215
[TBL] [Abstract][Full Text] [Related]
15. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
Lafay-Cousin L; Purdy E; Huang A; Cushing SL; Papaioannou V; Nettel-Aguirre A; Bouffet E
Pediatr Blood Cancer; 2013 Feb; 60(2):287-92. PubMed ID: 23002030
[TBL] [Abstract][Full Text] [Related]
16. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
17. Ototoxic impact of cisplatin in pediatric oncology patients.
Berg AL; Spitzer JB; Garvin JH
Laryngoscope; 1999 Nov; 109(11):1806-14. PubMed ID: 10569412
[TBL] [Abstract][Full Text] [Related]
18. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma.
Paulino AC; Lobo M; Teh BS; Okcu MF; South M; Butler EB; Su J; Chintagumpala M
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1445-50. PubMed ID: 20231075
[TBL] [Abstract][Full Text] [Related]
19. Hearing loss in pediatric cancer survivors treated with cisplatin.
Knight K
Oncology (Williston Park); 2008 Apr; 22(4 Suppl Nurse Ed):35-7. PubMed ID: 19856560
[No Abstract] [Full Text] [Related]
20. Hearing impairment after platinum-based chemotherapy in childhood.
Einar-Jon E; Trausti O; Asgeir H; Christian M; Thomas W; Måns M; Jon K; Hannes P
Pediatr Blood Cancer; 2011 Apr; 56(4):631-7. PubMed ID: 21298751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
